Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
C. Beauchemin, N. Letarte, K. Mathurin, L. Yelle & J. Lachaine. (2016) A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. Journal of Medical Economics 19:6, pages 619-629.
Read now
Read now
Noemi Muszbek, Noemi Kreif, Adriana Valderrama, Agnes Benedict, Jack Ishak & Dr. Paul Ross. (2012) Modelling survival in hepatocellular carcinoma. Current Medical Research and Opinion 28:7, pages 1141-1153.
Read now
Read now
Yong-Song Guan & Qing He. (2011) Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 12:2, pages 303-313.
Read now
Read now
Articles from other publishers (20)
Sydney C. Yuen, Adaeze Q. Amaefule, Hannah H. Kim, Breanna-Verissa Owoo, Emily F. Gorman & T. Joseph MattinglyIIII. (2021) A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. PharmacoEconomics - Open 6:1, pages 9-19.
Crossref
Crossref
Stephen J. Williams, William S. Rilling & Sarah B. White. (2021) Quality of Life and Cost Considerations: Y-90 Radioembolization. Seminars in Interventional Radiology 38:04, pages 482-487.
Crossref
Crossref
Paulo Henrique LimaBoyan FanJoshua BérubéMilena CernyDamien OliviéJeanne-Marie GiardCatherine BeaucheminAn Tang. (2019) Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. American Journal of Roentgenology 213:1, pages 17-25.
Crossref
Crossref
Nidhi Gupta, Rohan K. Verma, Shankar Prinja & Radha K. Dhiman. (2019) Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India. Journal of Clinical and Experimental Hepatology 9:4, pages 468-475.
Crossref
Crossref
Shukui Qin, Eliza Kruger, Seng Chuen Tan, Shuqun Cheng, Nanya Wang & Jun Liang. (2018) Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang & Ming Kuang. (2018) Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 18:1.
Crossref
Crossref
Hla-Hla Thein, Yao Qiao, Ahmad Zaheen, Nathaniel Jembere, Gonzalo Sapisochin, Kelvin K. W. Chan, Eric M. Yoshida & Craig C. Earle. (2017) Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLOS ONE 12:10, pages e0185198.
Crossref
Crossref
M B Hannouf, E Winquist, S M Mahmud, M Brackstone, S Sarma, G Rodrigues, P Rogan, J S Hoch & G S Zaric. (2016) Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. The Pharmacogenomics Journal 17:3, pages 286-300.
Crossref
Crossref
Fabrice Smieliauskas, Chun-Ru Chien, Chan Shen, Daniel M. Geynisman & Ya-Chen Tina Shih. (2014) Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review. PharmacoEconomics 32:7, pages 651-680.
Crossref
Crossref
Malek B. Hannouf, Bin Xie, Muriel Brackstone & Gregory S. Zaric. (2013) Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer. PharmacoEconomics 32:2, pages 135-147.
Crossref
Crossref
Michael C. Kreissl, Christian Jacob, Dagmar Führer, Wolfram Karges, Markus Luster, Michael P. Lux, Klaus Mann, Thomas Mittendorf, Matthias Schott, Christine Spitzweg & Hans-Joachim Schmoll. (2014) Best Supportive Care from the Conservative/Non-Surgical Perspective and Its Costs in the Treatment of Patients with Advanced Medullary Thyroid Cancer: Results of a Delphi Panel. Oncology Research and Treatment 37:6, pages 316-322.
Crossref
Crossref
Xin-Ji Zhang, Tian-Yi Zhang, Fei-Fei Yu, Xin Wei, Ye-Sheng Li, Feng Xu, Li-Xin Wei & Jia He. (2013) Risk of Treatment-related Mortality with Sorafenib in Patients with Cancer. Asian Pacific Journal of Cancer Prevention 14:11, pages 6681-6686.
Crossref
Crossref
Malek B Hannouf, Bin Xie, Muriel Brackstone & Gregory S Zaric. (2012) Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer. BMC Cancer 12:1.
Crossref
Crossref
Henning Wege & D. Arnold. (2013) Systemtherapie des Leberzellkarzinoms. Wiener klinisches Magazin 15:5, pages 26-30.
Crossref
Crossref
H. Wege & D. Arnold. (2012) Systemtherapie des LeberzellkarzinomsSystemic therapy of hepatocellular carcinoma. Der Onkologe 18:7, pages 602-610.
Crossref
Crossref
Philip J. Johnson. 2011. Clinical Dilemmas in Primary Liver Cancer. Clinical Dilemmas in Primary Liver Cancer
154
159
.
Augusto Villanueva & Josep M. Llovet. (2011) Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology 140:5, pages 1410-1426.
Crossref
Crossref
Brian I. Carr, Stuart Carroll, Noemi Muszbek & Kathleen Gondek. (2010) Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 25:11, pages 1739-1746.
Crossref
Crossref
Gillian M. Keating & Armando Santoro. (2009) Sorafenib. Drugs 69:2, pages 223-240.
Crossref
Crossref
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis & Zhongzhen Guan. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology 10:1, pages 25-34.
Crossref
Crossref